KTE-X19 CAR T cell therapy in relapsed or refractory mantle-cell lymphoma

Cited by (1,001)

Items 101–200 of 1,001

1. Advancing CAR T cell therapy through the use of multidimensional omics data
   Jingwen Yang, Yamei Chen, Ying Jing, Michael R. Green, Leng Han · 2023 · Nature Reviews Clinical Oncology
2. Enhanced CAR T-Cell Therapy for Lymphoma after Previous Failure
   Jakub Svoboda, Daniel Jeffrey Landsburg, James Nathan Gerson, Sunita Dwivedy Nasta, Stefan Klaus Barta, Elise A. Chong, Michael Roderick Cook, Noelle V. Frey, Joanne Shea, Amanda Cervini et al. · 2025 · New England Journal of Medicine
3. Born to survive: how cancer cells resist CAR T cell therapy
   Jean Lemoine, Marco Ruella, Roch Houot · 2021 · Journal of Hematology & Oncology
4. Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma
   Michael L. Wang, Wojciech J. Jurczak, Pier Luigi Zinzani, Toby Andrew Eyre, Chan Yoon Cheah, Chaitra Shankar Ujjani, Youngil Koh, Koji Izutsu, James Nathan Gerson, Ian W. Flinn et al. · 2023 · Journal of Clinical Oncology
5. Reactions Related to CAR-T Cell Therapy
   Lele Miao, Zhengchao Zhang, Zhijian Ren, Yumin Li · 2021 · Frontiers in Immunology
6. Prophylactic tocilizumab prior to anti-CD19 CAR-T cell therapy for non-Hodgkin lymphoma
   Caimi, Paolo F., Pacheco Sanchez, Gabriela, Sharma, Ashish, Otegbeye, Folashade, Ahmed, Nausheen, Rojas, Patricio, Patel, Seema, Kleinsorge Block, Sarah, Schiavone, Jennifer, Zamborsky, Kayla et al. · 2021 · Frontiers in Immunology
7. Size-dependent activation of CAR-T cells
   Qian Xiao, Xinyan Zhang, Liqun Tu, Jian Ping Cao, Christian S. Hinrichs, Xiaolei Su · 2022 · Science Immunology
8. CAR T-cell therapy for B-cell lymphoma
   Nathan Denlinger, David Alan Bond, Samantha Mary Jaglowski · 2021 · Current Problems in Cancer
9. Barriers to Chimeric Antigen Receptor T-Cell (CAR-T) Therapies in Clinical Practice
   Ajeet Gajra, Abigail A. Zalenski, Aishwarya Sannareddy, Yolaine Jeune‐Smith, Kandice A. Kapinos, Ankit J. Kansagra · 2022 · Pharmaceutical Medicine
10. Lisocabtagene Maraleucel in Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis of the Mantle Cell Lymphoma Cohort From TRANSCEND NHL 001, a Phase I Multicenter Seamless Design Study
    Michael L. Wang, Tanya Siddiqi, Leo I. Gordon, Manali Kirtikumar Kamdar, Matthew Alexander Lunning, Alexandre V. Vinaud Hirayama, Jeremy S. Abramson, Jon E. Arnason, Nilanjan Ghosh, Amitkumar Mehta et al. · 2023 · Journal of Clinical Oncology
11. Second Primary Malignancies after CAR T-Cell Therapy: A Systematic Review and Meta-analysis of 5,517 Lymphoma and Myeloma Patients
    Tobias Tix, Mohammad Alhomoud, Roni Shouval, Edward R. Scheffer Cliff, Miguel‐Angel Perales, David M. Cordas dos Santos, Kai Rejeski · 2024 · Clinical Cancer Research
12. Cost of decentralized CAR T‐cell production in an academic nonprofit setting
    Tao Ran, Stefan B. Eichmüller, Patrick Schmidt, Michael Schlander · 2020 · International Journal of Cancer
13. The Application of Nanobody in CAR-T Therapy
    Chaolemeng Bao, Quanli Gao, Linlin Li, Lu Han, Bingxiang Zhang, Yijin Ding, Zongpei Song, Ruining Zhang, Jishuai Zhang, Xian-Hui Wu · 2021 · Biomolecules
14. TNBC: Potential Targeting of Multiple Receptors for a Therapeutic Breakthrough, Nanomedicine, and Immunotherapy
    Desh Deepak Singh, Dharmendra Kumar Yadav · 2021 · Biomedicines
15. Infections after chimeric antigen receptor (CAR)‐T‐cell therapy for hematologic malignancies
    Eleftheria Kampouri, Jessica S Little, Kai Rejeski, Oriol Manuel, Sarah Page Hammond, Joshua Aiden Hill · 2023 · Transplant Infectious Disease
16. The translational challenges of precision oncology
    Oriol Pich, Chris Bailey, Thomas B.K. Watkins, Simone Zaccaria, Mariam Jamal‐Hanjani, Charles Swanton · 2022 · Cancer Cell
17. CAR-T Cell Therapy: Mechanism, Management, and Mitigation of Inflammatory Toxicities
    Joseph W. Fischer, Nirjal Bhattarai · 2021 · Frontiers in Immunology
18. Engineering the next generation of CAR-NK immunotherapies
    Alexander Biederstädt, Katayoun Rezvani · 2021 · International Journal of Hematology
19. Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T Cells Administered Intravenously in Patients with Melanoma and Breast Carcinoma
    Payal Deepak Shah, Alexander Chan Chi Huang, Xiaowei Xu, Robert J. Orlowski, Ravi K. Amaravadi, Lynn Mara Schuchter, Paul J. Zhang, Julia C. Tchou, Tina Matlawski, Amanda Cervini et al. · 2023 · Cancer Research Communications
20. Long-term activity of tandem CD19/CD20 CAR therapy in refractory/relapsed B-cell lymphoma: a single-arm, phase 1–2 trial
    Ya-Jing Zhang, Yao Wang, Yang Liu, Chuan Tong, Chun-Meng Wang, Ye-Lei Guo, Dong-dong Ti, Qing-Ming Yang, Shen Qiao, Zhi-Qiang Wu et al. · 2021 · Leukemia
21. Engineered T cell therapy for viral and non-viral epithelial cancers
    Scott Michael Norberg, Christian S. Hinrichs · 2022 · Cancer Cell
22. Graft‐versus‐host disease risk after chimeric antigen receptor T‐cell therapy: the diametric opposition of T cells
    Khaled S. Sanber, Bipin N. Savani, Tania Jain · 2021 · British Journal of Haematology
23. Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma
    Constantine Si Lun Tam, Stephen Opat, David Simpson, Gavin Cull, Javier L Munoz, Tycel Jovelle Phillips, Won Seog Kim, Simon A. Rule, Siminder Kaur Atwal, Rachel Wei et al. · 2021 · Blood Advances
24. EBV-associated diseases: Current therapeutics and emerging technologies
    Srishti Chakravorty, Behdad Afzali, Majid Kazemian · 2022 · Frontiers in Immunology
25. CAR-T Cell Therapy: From the Shop to Cancer Therapy
    Ashanti Concepción Uscanga‐Palomeque, Ana Karina Chávez-Escamilla, Cynthia Aracely Alvizo-Báez, Santiago Saavedra-Alonso, Luis Daniel Terrazas-Armendáriz, Reyes Támez-Guerra, Cristina Rodrı́guez-Padilla, Juan Manuel Alcocer-González · 2023 · International Journal of Molecular Sciences
26. CAR T-Cell Therapy for B-Cell non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia: Clinical Trials and Real-World Experiences
    Candida Vitale, Paolo Strati · 2020 · Frontiers in Oncology
27. CAR-T cell potency: from structural elements to vector backbone components
    Marzieh Mazinani, Fatemeh Rahbarizadeh · 2022 · Biomarker Research
28. Advances in immunotherapy for glioblastoma multiforme
    Ahmad Bakur Mahmoud, Reham Ajina, Sarah Aref, Manar Darwish, May A. Alsayb, Mustafa Taher, Shaker T. Alsharif, Anwar M. Hashem, Almohanad A. Alkayyal · 2022 · Frontiers in Immunology
29. Tuning the ignition of CAR: optimizing the affinity of scFv to improve CAR-T therapy
    Yanting Duan, Ruoqi Chen, Yanjie Huang, Xianhui Meng, Jiangqing Chen, Chan Liao, Yongmin Tang, Chun Zhou, Xiaofei Gao, Jie Sun · 2021 · Cellular and Molecular Life Sciences
30. Cardiotoxicity from chimeric antigen receptor-T cell therapy for advanced malignancies
    Matthias Totzeck, Lars Michel, Yi Lin, Joerg Herrmann, Tienush Rassaf · 2022 · European Heart Journal
31. Cytopenia after CAR-T Cell Therapy—A Brief Review of a Complex Problem
    Naman Sharma, Patrick Michael Reagan, Jane L. Liesveld · 2022 · Cancers
32. A long-acting interleukin-7, rhIL-7-hyFc, enhances CAR T cell expansion, persistence, and anti-tumor activity
    Miriam Y. Kim, Reyka G. Jayasinghe, Jessica Merritt Devenport, Julie Ritchey, Michael P. Rettig, Julie O’Neal, Karl William Staser, Krista Kennerly, Alun J. Carter, Feng Gao et al. · 2022 · Nature Communications
33. Dose–response correlation for CAR-T cells: a systematic review of clinical studies
    Anand Rotte, Matthew J. Frigault, Ayub Ansari, Brad Gliner, Christopher Ryan Heery, Bijal Dinesh Shah · 2022 · Journal for ImmunoTherapy of Cancer
34. Clinical Cancer Advances 2021: ASCO's Report on Progress Against Cancer
    Sonali M. Smith, KERRI WACHTER, Howard A. Burris, Richard L. Schilsky, Daniel J. George, Douglas E. Peterson, Melissa Lynne Johnson, Merry Jennifer Markham, Kathryn Finch Mileham, Muhammad Shaalan Beg et al. · 2021 · Journal of Clinical Oncology
35. Bendamustine is safe and effective for lymphodepletion before tisagenlecleucel in patients with refractory or relapsed large B-cell lymphomas
    Guido Ghilardi, Elise A. Chong, Jakub Svoboda, Philipp Wohlfarth, Sunita Dwivedy Nasta, Staci Williamson, J.D. Landsburg, James Nathan Gerson, Stefan Klaus Barta, Raymone Pajarillo et al. · 2022 · Annals of Oncology
36. IL12 immune therapy clinical trial review: Novel strategies for avoiding CRS-associated cytokines
    Zhiliang Jia, Dristhi S. Ragoonanan, Kris Michael Mahadeo, Jonathan Benjamin Gill, Richard Greg Gorlick, Elizabeth Shpal, Shulin Li · 2022 · Frontiers in Immunology
37. Infectious complications of CAR T-cell therapy: a clinical update
    Adam G. Stewart, Andrea S. Henden · 2021 · Therapeutic Advances in Infectious Disease
38. Modulation of BCL-2 in Both T Cells and Tumor Cells to Enhance Chimeric Antigen Receptor T-cell Immunotherapy against Cancer
    Yong Gu Lee, Puneeth Guruprasad, Guido Ghilardi, Raymone Pajarillo, Christopher Tor Sauter, Ruchi P. Patel, Hatcher J. Ballard, Seok Jae Hong, Inkook Chun, Nicholas Yang et al. · 2022 · Cancer Discovery
39. Understanding CAR T cell-tumor interactions: Paving the way for successful clinical outcomes
    Felix Korell, Trisha R. Berger, Marcela Valderrama Maus · 2022 · Med
40. CXCR4 in Waldenström’s Macroglobulinema: chances and challenges
    Lisa Kaiser, Zachary R. Hunter, Steven Peter Treon, Christian Buske · 2020 · Leukemia
41. The EBMT/EHA CAR-T Cell Handbook
    Nicolaus Kröger, John G. Gribben, Christian Chabannon, Ibrahim Yakoub‐Agha, Hermann Einsele · 2022 · Springer eBooks
42. PET/CT in Non-Hodgkin Lymphoma: An Update
    Lucia Zanoni, Davide Bezzi, Cristina Nanni, Andrea Paccagnella, Arianna Farina, Alessandro Broccoli, Beatrice Casadei, Pier Luigi Zinzani, Stefano Fanti · 2022 · Seminars in Nuclear Medicine
43. Engineered CAR-T cells targeting TAG-72 and CD47 in ovarian cancer
    Runzhe Shu, Vera J. Evtimov, Maree V. Hammett, Nhu-Y. N. Nguyen, Junli Zhuang, Peter J. Hudson, Maureen Howard, Aleta Pupovac, Alan O. Trounson, Richard L. Boyd · 2021 · Molecular Therapy — Oncolytics
44. Overcoming tumor resistance mechanisms in CAR-NK cell therapy
    Antonio Valeri, Almudena García-Ortiz, Eva Castellano, Laura Córdoba, Elena Maroto-Martín, Jessica Encinas, Alejandra Leivas, Paula Río, Joaquín Martínez‐López · 2022 · Frontiers in Immunology
45. Cardiovascular Toxicities of Immune Therapies for Cancer – A Scientific Statement of the Heart Failure Association (HFA) of the ESC and the ESC Council of Cardio-Oncology
    Carlo Gabriele Tocchetti, Dimitrios T. Farmakis, Yvonne Koop, María Sol Andrés, Liam S. Couch, Luigi Formisano, Fortunato Ciardiello, Fabrizio Pane, Lewis Au, Max Emmerich et al. · 2024 · European Journal of Heart Failure
46. Impact of T cell characteristics on CAR-T cell therapy in hematological malignancies
    Zhongfei Tao, Zuzana Chyra, Jana Kotulová, Piotr Celichowski, Jana Mihályová, Sandra Charvátová, Roman Hájek · 2024 · Blood Cancer Journal
47. The next wave of cellular immunotherapies in pancreatic cancer
    Dannel Yeo, Caroline Giardina, Payal Saxena, John E.J. Rasko · 2022 · Molecular Therapy — Oncolytics
48. Current Status and Perspectives of Dual-Targeting Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Hematological Malignancies
    Bailu Xie, Zhengdong Li, Jianfeng Zhou, Wen Wang · 2022 · Cancers
49. Applying a clinical lens to animal models of CAR-T cell therapies
    Brynn B. Duncan, Cynthia E. Dunbar, Kazusa Ishii · 2022 · Molecular Therapy — Methods & Clinical Development
50. Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma
    Gloria Iacoboni, Kai Rejeski, Guillermo Javierre Villacampa, Jaap A. van Doesum, Annalisa Chiappella, Francesca Bonifazi, Lucía López‐Corral, Michiel C. van Aalderen, Mi Kwon, Núria Martínez‐Cibrián et al. · 2022 · Blood Advances
51. Polymer- and lipid-based gene delivery technology for CAR T cell therapy
    Inês S. Pinto, Rosemeyre A. Cordeiro, Henrique Faneca · 2022 · Journal of Controlled Release
52. YTHDF2 promotes ATP synthesis and immune evasion in B cell malignancies
    Zhenhua Chen, Chengwu Zeng, Lu Yang, Yuan Che, Meiling Chen, Lillian Sau, Bintao Wang, Keren Zhou, Yu Chen, Ying Qing et al. · 2024 · Cell
53. Befriending the Hostile Tumor Microenvironment in CAR T-Cell Therapy
    Lorenzo Lindo, Lauren Wilkinson, Kevin Anthony Hay · 2021 · Frontiers in Immunology
54. Role of Immunotherapy in the Treatment of Cancer: A Systematic Review
    Sia Pei Ling, Long Chiau Ming, Jagjit Singh Dhaliwal, Madhu Gupta, Chrismawan Ardianto, Khang Wen Goh, Zahid Hussain, Naeem Shafqat · 2022 · Cancers
55. Improving outcomes and mitigating costs associated with CAR T-cell therapy
    Rebecca Borgert, PharmD, BCOP; · 2021 · The American Journal of Managed Care
56. An orthogonal IL-2 and IL-2Rβ system drives persistence and activation of CAR T cells and clearance of bulky lymphoma
    Paul-Joseph P. Aspuria, Sandro Vivona, Michele Bauer, Marie Semana, Navneet P. Ratti, Scott McCauley, Romina M. Riener, René de Waal Malefyt, Deepti Rokkam, Jan Emmerich et al. · 2021 · Science Translational Medicine
57. Construction of PD1/CD28 chimeric-switch receptor enhances anti-tumor ability of c-Met CAR-T in gastric cancer
    Cong Chen, Yanmei Gu, Fan Zhang, Zheng-Chao Zhang, Yating Zhang, Yi-Di He, Ling Wang, Ning Zhou, Futian Tang, Hongjian Liu et al. · 2021 · OncoImmunology
58. Antibodies against vaccine-preventable infections after CAR-T cell therapy for B cell malignancies
    Carla Simone Walti, Elizabeth M. Krantz, Joyce Maalouf, Jim B. Boonyaratanakornkit, Jacob Keane-Candib, Laurel Joncas-Schronce, Terry Stevens‐Ayers, Sayan Dasgupta, Justin J. Taylor, Alexandre V. Vinaud Hirayama et al. · 2021 · JCI Insight
59. Utility of a safety switch to abrogate CD19.CAR T-cell–associated neurotoxicity
    Matthew Charles Foster, Barbara Savoldo, Winnie Lau, Clio Rubiños, Natalie Sophia Grover, Paul M. Armistead, James M. Coghill, Robert S. Hagan, Kaitlin Morrison, Faith Brianne Buchanan et al. · 2021 · Blood
60. Highly Efficient Transfection of Human Primary T Lymphocytes Using Droplet-Enabled Mechanoporation
    Byeongju Joo, Jeongsoo Hur, Gi-Beom Kim, Seung Gyu Yun, Aram J. Chung · 2021 · ACS Nano
61. Price and Prejudice? The Value of Chimeric Antigen Receptor (CAR) T-Cell Therapy
    Gyeyoung Choi, Gyeongseon Shin, SeungJin Bae · 2022 · International Journal of Environmental Research and Public Health
62. High-throughput continuous-flow microfluidic electroporation of mRNA into primary human T cells for applications in cellular therapy manufacturing
    Charles A. Lissandrello, José A. L. Santos, Peter T. Hsi, Michaela Welch, Vienna L. Mott, Ernest S. Kim, Jordan Chesin, Nerses J. Haroutunian, Aaron G. Stoddard, Andrew Czarnecki et al. · 2020 · Scientific Reports
63. A nonviral, nonintegrating DNA nanovector platform for the safe, rapid, and persistent manufacture of recombinant T cells
    Matthias Bozza, Alice De Roia, Margareta P. Correia, Aileen Berger, Alexandra Tuch, Andreas Schmidt, Inka Zörnig, Dirk Jäger, Patrick Schmidt, Richard Paul Harbottle · 2021 · Science Advances
64. Engineering Gene Therapy: Advances and Barriers
    Alireza Shahryari, Ingo Burtscher, Zahra Nazari, Heiko Lickert · 2021 · Advanced Therapeutics
65. Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study
    Bijal Dinesh Shah, Armin Ghobadi, Olalekan O. Oluwole, Aaron C. Logan, Nicolas Boissel, Ryan Daniel Cassaday, Thibaut Leguay, Michael Russell Bishop, Max S. Topp, Dimitrios Tzachanis et al. · 2022 · Journal of Hematology & Oncology
66. CAR T cells and time-limited ibrutinib as treatment for relapsed/refractory mantle cell lymphoma: the phase 2 TARMAC study
    Adrian G. Minson, Nada Hamad, Chan Yoon Cheah, Constantine Si Lun Tam, Piers A. Blombery, David Westerman, David Ritchie, Huw Morgan, Nicholas Holzwart, Stephen Lade et al. · 2023 · Blood
67. Targeted in vivo delivery of genetic medicines utilizing an engineered lentiviral vector platform results in CAR T and NK cell generation
    James I. Andorko, Ronnie M. Russell, Bruce C. Schnepp, Daniel Grubaugh, Karla F Mullen, Aoi Wakabayashi, Léolène J Carrington, Thomas M. O’Malley, Leticia Kuri-Cervantes, Timothy D. Culp et al. · 2025 · Molecular Therapy
68. Incidence and risk factors associated with bleeding and thrombosis following chimeric antigen receptor T-cell therapy
    Andrew J. Johnsrud, Juliana K. Craig, John H. Baird, Jay Y. Spiegel, Lori S. Muffly, James L. Zehnder, John S. Tamaresis, Robert S. Negrin, Laura Johnston, Sally Arai et al. · 2021 · Blood Advances
69. Approved CAR-T therapies have reproducible efficacy and safety in clinical practice
    Daniel Goyco Vera, Hiral Waghela, Mohamed Nuh, Jonathan Z. Pan, Premal Lulla · 2024 · Human Vaccines & Immunotherapeutics
70. The emerging roles of NGS in clinical oncology and personalized medicine
    Bashdar Mahmud Hussen, Sara Tharwat Abdullah, Abbas Burhan Salihi, Dana Khdr Sabir, Karzan R. Sidiq, Mohammed Fatih Rasul, Hazha Jamal Hidayat, Soudeh Ghafouri‐Fard, Mohammad Naser Taheri, Elena Jamali · 2022 · Pathology - Research and Practice
71. Applying the EHA/EBMT grading for ICAHT after CAR-T: comparative incidence and association with infections and mortality
    Kai Rejeski, Yucai Wang, Doris K. Hansen, Gloria Iacoboni, Emmanuel Bachy, Radhika Bansal, Olaf Penack, Fabian Müller, Wolfgang Andreas Bethge, Javier L Munoz et al. · 2024 · Blood Advances
72. Managing hypogammaglobulinemia in patients treated with CAR-T-cell therapy: key points for clinicians
    Eleftheria Kampouri, Carla Simone Walti, Jordan Gauthier, Joshua Aiden Hill · 2022 · Expert Review of Hematology
73. TIGIT is the central player in T-cell suppression associated with CAR T-cell relapse in mantle cell lymphoma
    Changying Jiang, Dapeng Hao, Preetesh Jain, Yijing Li, Qingsong Cai, Yixin Yao, Lei Nie, Yang Liu, Jingling Jin, Wei Wang et al. · 2022 · Molecular Cancer
74. Advanced Flow Cytometry Assays for Immune Monitoring of CAR-T Cell Applications
    Ulrich Blache, Ronald Weiss, Andreas Boldt, Michael Kapinsky, André‐René Blaudszun, Andrea Quaiser, Annabelle Pohl, Tewfik Miloud, Mégane Burgaud, Vladan Vučinić et al. · 2021 · Frontiers in Immunology
75. Critical care management of chimeric antigen receptor T‐cell therapy recipients
    Alexander Shimabukuro‐Vornhagen, Boris Böll, Peter Schellongowski, Sandrine Valade, Victoria Metaxa, Élie Azoulay, Michael von Bergwelt‐Baildon · 2021 · CA A Cancer Journal for Clinicians
76. Cardiotoxicity of T-Cell Antineoplastic Therapies
    Sarju Ganatra, Sourbha S. Dani, Eric H. Yang, Vlad Gabriel Zaha, Anju Nohria · 2022 · JACC CardioOncology
77. Mechanisms of Resistance and Treatment of Relapse after CAR T-cell Therapy for Large B-cell Lymphoma and Multiple Myeloma
    Kai Rejeski, Michael David Jain, Eric L. Smith · 2023 · Transplantation and Cellular Therapy
78. Promises and challenges of a decentralized CAR T-cell manufacturing model
    Shah, Manan, Krull, Ashley, Odonnell, Lynn, de Lima, Marcos J., Bezerra, Evandro · 2023 · Frontiers in Transplantation
79. Targeting loss of heterozygosity for cancer-specific immunotherapy
    Michael S. Hwang, Brian J. Mog, Jacqueline Douglass, Alexander H. Pearlman, Emily Han-Chung Hsiue, Suman Paul, Sarah R. DiNapoli, Maximilian F. Konig, Drew M. Pardoll, Sandra B. Gabelli et al. · 2021 · Proceedings of the National Academy of Sciences
80. Systematic Review of Available CAR-T Cell Trials around the World
    Luciana Rodrigues Carvalho Barros, Samuel Campanelli Freitas Couto, Daniela Silva Santurio, Emanuelle Arantes Paixão, Fernanda C. Cardoso, Viviane Jennifer da Silva, Paulo Henrique dos Santos Klinger, Paula do Amaral Costa Ribeiro, Felipe Augusto Rós, Théo Gremen Mimary de Oliveira et al. · 2022 · Cancers
81. A comparison of the International Consensus and 5th World Health Organization classifications of mature B-cell lymphomas
    Brunangelo Falini, Giovanni Martino, Stefano Lazzi · 2022 · Leukemia
82. Advances in CAR T cell therapy: antigen selection, modifications, and current trials for solid tumors
    Safwaan H. Khan, Yeonjoo Choi, Mysore S. Veena, John K. Lee, Daniel Sanghoon Shin · 2025 · Frontiers in Immunology
83. Therapeutic options for relapsed/refractory mantle cell lymphoma
    Toby Andrew Eyre, Chan Yoon Cheah, Michael L. Wang · 2021 · Blood
84. Effect of early granulocyte-colony-stimulating factor administration in the prevention of febrile neutropenia and impact on toxicity and efficacy of anti-CD19 CAR-T in patients with relapsed/refractory B-cell lymphoma
    Raphaël Liévin, Roberta Di Blasi, Florence Morin, Eugenio Galli, Vincent Allain, Romain de Jorna, Laëtitia Vercellino, Nathalie Parquet, Miryam Mebarki, Jérôme Larghero et al. · 2022 · Bone Marrow Transplantation
85. Glofitamab in Relapsed/Refractory Mantle Cell Lymphoma: Results From a Phase I/II Study
    Tycel Jovelle Phillips, Carmelo Carlo‐Stella, Franck Morschhauser, Emmanuel Bachy, Michael Crump, Marek Trněný, Nancy L. Bartlett, Jan Maciej Zaucha, Tomasz Wróbel, Fritz C. Offner et al. · 2024 · Journal of Clinical Oncology
86. Non-ICANS neurological complications after CAR T-cell therapies: recommendations from the EBMT Practice Harmonisation and Guidelines Committee
    Charlotte Graham, Roser Velasco, Ana Alarcón Tomás, Orla Stewart, Guillaume Dachy, Francesca Del Bufalo, Matteo Doglio, Jan‐Inge Henter, Guillermo Ortí, Zinaida Perić et al. · 2025 · The Lancet Oncology
87. EASIX and Severe Endothelial Complications After CD19-Directed CAR-T Cell Therapy—A Cohort Study
    Felix Korell, Olaf Penack, Mike Mattie, Nicholas Schreck, Axel Benner, Julia Krzykalla, Zixing Wang, Michael W. Schmitt, Lars Bullinger, Carsten Müller‐Tidow et al. · 2022 · Frontiers in Immunology
88. Blinatumomab in pediatric relapsed/refractory B-cell acute lymphoblastic leukemia: RIALTO expanded access study final analysis
    Franco Locatelli, Gerhard Zugmaier, Noemi Mergen, Peter Bader, Sima Jeha, Paul‐Gerhardt Schlegel, Jean‐Pierre Bourquin, Rupert Handgretinger, Benoît Brethon, Claudia Rössig et al. · 2022 · Blood Advances
89. Tissue-resident memory CAR T cells with stem-like characteristics display enhanced efficacy against solid and liquid tumors
    In-Young Jung, Estela Noguera-Ortega, Robert L. Bartoszek, Sierra M. Collins, Erik F. Williams, Megan M. Suhoski, Julie K. Jadlowsky, Gabriela Plesa, Don L. Siegel, Anne Chew et al. · 2023 · Cell Reports Medicine
90. Fine-Tuning through Generations: Advances in Structure and Production of CAR-T Therapy
    Zhibo Zheng, Siyuan Li, Mohan Liu, Chuyan Chen, Lu Zhang, Daobin Zhou · 2023 · Cancers
91. Cytokine Release Syndrome Biology and Management
    Dustin A. Cobb, Daniel W. Lee · 2021 · The Cancer Journal
92. Expanded human NK cells armed with CAR uncouple potent anti-tumor activity from off-tumor toxicity against solid tumors
    Ana L. Portillo, Richard Hogg, Sophie M. Poznanski, Eduardo A. Peña Rojas, Niamh J. Cashell, Joanne A. Hammill, Marianne V. Chew, Mira M. Shenouda, Tyrah M. Ritchie, Quynh Cao et al. · 2021 · iScience
93. Genome-edited allogeneic donor “universal” chimeric antigen receptor T cells
    Waseem Qasim · 2022 · Blood
94. Biomarkers for prediction of CAR T therapy outcomes: current and future perspectives
    Lucija Sršen, Larisa Janžič, Alojz Ihan, Andreja Nataša Kopitar · 2024 · Frontiers in Immunology
95. CD38 as a pan-hematologic target for chimeric antigen receptor T cells
    Tina Glisovic‐Aplenc, Caroline J. Diorio, John A. Chukinas, Kimberly Veliz, Olga E. Shestova, Feng Shen, Selene Nuñez-Cruz, Tiffaney L. Vincent, Fei Miao, Michael C. Milone et al. · 2023 · Blood Advances
96. The Advent of CAR T-Cell Therapy for Lymphoproliferative Neoplasms: Integrating Research Into Clinical Practice
    Marco Cerrano, Marco Ruella, Miguel‐Angel Perales, Candida Vitale, Danilo Faraci, Luisa Giaccone, Marta Coscia, Molly Maloy, Miriam Sánchez‐Escamilla, Hesham Elsabah et al. · 2020 · Frontiers in Immunology
97. Toward Better Understanding and Management of CAR-T Cell–Associated Toxicity
    Andrea Schmidts, Marc Wehrli, Marcela Valderrama Maus · 2020 · Annual Review of Medicine
98. Early Use of Corticosteroids following CAR T-Cell Therapy Correlates with Reduced Risk of High-Grade CRS without Negative Impact on Neurotoxicity or Treatment Outcome
    Tim Lakomy, Dilara Akhoundova, Henning Nilius, Marie-Noëlle Kronig, Urban Novak, Michael Daskalakis, Ulrike Bacher, Thomas Pabst · 2023 · Biomolecules
99. CAR‐T cell therapy in hematological malignancies: Where are we now and where are we heading for?
    Aalia N. Khan, Sweety Asija, Juber Pendhari, Rahul Purwar · 2023 · European Journal Of Haematology
100. Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell Lymphoma
     Michael L. Wang, David Belada, David Belada, Yuqin Song, Wojciech J. Jurczak, Brad S. Kahl, Jonas Paludo, Michael Patvin Chu, Iryna Kryachok, Laura Fogliatto et al. · 2025 · Journal of Clinical Oncology